Relationship Between Venetoclax Exposure and Undetectable Minimal Residual Disease Rates in Relapsed/Refractory Patients With Chronic Lymphocytic Leukemia: A Pooled Analysis of Six Clinical Studies

• Sathej Gopalakrishnan,
• Rajeev Menon,
• Ahmed A. Suleiman,
• Arnon P. Kater,
• Stephan Stilgenbauer,
• John F. Seymour,
• Brenda Chyla,
• Tong Lu,
• Su Young Kim,
• Andrew W. Roberts,
• Jennifer A. Woyach,
• Sven Mensing,
• Ahmed Hamed Salem

Affiliations

Sathej Gopalakrishnan

1 Clinical Pharmacology, AbbVie, Ludwigshafen, Germany

Rajeev Menon

2 Clinical Pharmacology, AbbVie, North Chicago, IL, USA

Ahmed A. Suleiman

1 Clinical Pharmacology, AbbVie, Ludwigshafen, Germany

Arnon P. Kater

3 Department of Hematology, Cancer Center Amsterdam, Amsterdam University Medical Center, on behalf of HOVON CLL WG, Amsterdam, The Netherlands

Stephan Stilgenbauer

4 Division of CLL, Department III of Internal Medicine, Ulm University, Ulm, Germany

John F. Seymour

5 Department of Hematology, The Royal Melbourne Hospital and Peter MacCallum Cancer Centre, University of Melbourne, Parkville, VIC, Australia

Brenda Chyla

6 Precision Medicine Oncology, AbbVie, North Chicago, IL, USA

Tong Lu

7 Genentech Inc, South San Francisco, CA, USA

Su Young Kim

8 Oncology Development, AbbVie, North Chicago, IL, USA

Andrew W. Roberts

5 Department of Hematology, The Royal Melbourne Hospital and Peter MacCallum Cancer Centre, University of Melbourne, Parkville, VIC, Australia

Jennifer A. Woyach

9 Comprehensive Cancer Center, The Ohio State University, Columbus, OH, USA

Sven Mensing

1 Clinical Pharmacology, AbbVie, Ludwigshafen, Germany

Ahmed Hamed Salem

2 Clinical Pharmacology, AbbVie, North Chicago, IL, USA